{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:22:10Z","timestamp":1740144130719,"version":"3.37.3"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T00:00:00Z","timestamp":1657238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T00:00:00Z","timestamp":1657238400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100010883","name":"Traditional Chinese Medicine Bureau of Guangdong Province","doi-asserted-by":"publisher","award":["20194005"],"award-info":[{"award-number":["20194005"]}],"id":[{"id":"10.13039\/501100010883","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Cervical cancer is the fourth most common malignancy in women, which is threatening female reproductive tract health. Chemotherapy can be used for neoadjuvant therapy of locally advanced cervical cancer and postoperative adjuvant therapy for patients with high-risk factors, so as to reduce the focus, sensitize radiotherapy, and reduce recurrence. The current first-line treatment is paclitaxel combined with platinum. Many literature studies have found that As<jats:sub>2<\/jats:sub>O<jats:sub>3<\/jats:sub> alone or in combination with platinum drugs have good efficacy in a variety of tumors both in vivo and in vitro. Moreover, our research group has verified that the efficacy of As<jats:sub>2<\/jats:sub>O<jats:sub>3<\/jats:sub> combined with platinum drugs in the treatment of cervical cancer is not inferior to the traditional first-line regimen at the cellular and animal levels, and paclitaxel is more expensive than As<jats:sub>2<\/jats:sub>O<jats:sub>3<\/jats:sub>. Hence, we aim to evaluate the clinical efficacy and safety of neoadjuvant chemotherapy with As<jats:sub>2<\/jats:sub>O<jats:sub>3<\/jats:sub> and carboplatin in locally advanced cervical cancer.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Sixty participants in the IB2, IIA2, and IIB stages of cervical cancer will be recruited in this study. After excluding patients who did not meet the criteria, they were randomly assigned to two groups in a 1:1 ratio. All patients underwent colposcopic biopsies to confirm the diagnosis and detailed clinical examinations. Eligible patients will receive either 2 cycles of paclitaxel and carboplatin or As<jats:sub>2<\/jats:sub>O<jats:sub>3<\/jats:sub> and carboplatin every 3 weeks. Patients were assessed for clinical efficacy after the second cycle of chemotherapy. Patients who had disease stable or disease progression at these time points will receive concurrent chemotherapy and radiation directly, while responders will receive PiverRutledge grade III radical hysterectomy and bilateral pelvic lymphadenectomy. Both groups of patients undergoing radical hysterectomy were given adjuvant therapy as per protocol-defined criteria. The efficacy and toxicity of the two groups were evaluated according to WHO acute and subacute toxicity classification standards.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>This is the first single-center, prospective, two-arm design, open-label randomized control trial that will evaluate the clinical efficacy and safety of neoadjuvant chemotherapy with As<jats:sub>2<\/jats:sub>O<jats:sub>3<\/jats:sub> and carboplatin in locally advanced cervical cancer.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p><jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.chictr.org.cn\/index.aspx\">ChineseClinicalTrialRegistry<\/jats:ext-link><jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.chictr.org.cn\/showproj.aspx?proj=39286\">ChiCTR1900023822<\/jats:ext-link>. Registered on 13 June 2019.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13063-022-06489-1","type":"journal-article","created":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T12:03:38Z","timestamp":1657281818000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["A prospective trial to evaluate the clinical efficacy and safety of neoadjuvant chemotherapy with arsenic trioxide and carboplatin in locally advanced cervical cancer: a study protocol for randomized controlled clinical"],"prefix":"10.1186","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6895-093X","authenticated-orcid":false,"given":"Ze Yang","family":"He","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hai Ying","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiao","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Si Jin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dao Cheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhong Zhe","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,7,8]]},"reference":[{"issue":"3","key":"6489_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin."},{"key":"6489_CR2","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology, cervical cancer, version 1.2021\u2014Oct 2, 2020. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cervical.pdf."},{"issue":"9","key":"6489_CR3","doi-asserted-by":"publisher","first-page":"4819","DOI":"10.21873\/anticanres.14485","volume":"40","author":"A Gadducci","year":"2020","unstructured":"Gadducci A, Cosio S. Neoadjuvant chemotherapy in locally advanced cervical cancer: review of the literature and perspectives of clinical research. Anticancer Res. 2020;40(9):4819\u201328.","journal-title":"Anticancer Res."},{"issue":"2","key":"6489_CR4","first-page":"CD001774","volume":"2004","author":"Neoadjuvant Chemotherapy for Cervical Cancer Meta-Analysis Collaboration (NACCCMA) Collaboration","year":"2004","unstructured":"Neoadjuvant Chemotherapy for Cervical Cancer Meta-Analysis Collaboration (NACCCMA) Collaboration. Neoadjuvant chemotherapy for locally advanced cervix cancer. Cochrane Database Syst Rev. 2004;2004(2):CD001774.","journal-title":"Cochrane Database Syst Rev."},{"issue":"1","key":"6489_CR5","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1200\/JCO.2002.20.1.179","volume":"20","author":"P Benedetti-Panici","year":"2002","unstructured":"Benedetti-Panici P, Greggi S, Colombo A, Amoroso M, Smaniotto D, Giannarelli D, et al. Neoadjuvant chemotherapy and radical surgery versus exclusive radiotherapy in locally advanced squamous cell cervical cancer: results from the Italian multicenter randomized study. J Clin Oncol. 2002;20(1):179\u201388.","journal-title":"J Clin Oncol."},{"issue":"17","key":"6489_CR6","doi-asserted-by":"publisher","first-page":"2470","DOI":"10.1016\/S0959-8049(03)00425-8","volume":"39","author":"Neoadjuvant Chemotherapy for Locally Advanced Cervical Cancer Meta-analysis Collaboration","year":"2003","unstructured":"Neoadjuvant Chemotherapy for Locally Advanced Cervical Cancer Meta-analysis Collaboration. Neoadjuvant chemotherapy for locally advanced cervical cancer: a systematic review and meta-analysis of individual patient data from 21 randomised trials. Eur J Cancer. 2003;39(17):2470\u201386.","journal-title":"Eur J Cancer."},{"key":"6489_CR7","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1046\/j.1525-1438.1998.09862.x","volume":"8","author":"JE Sardi","year":"1998","unstructured":"Sardi JE, Sananes CE, Giaroli A, et al. Neoadjuvant chemotherapy in cervical carcinoma stage IIB: a randomized controlled trial. Int J Gynecol Cancer. 1998;8:441\u201350.","journal-title":"Int J Gynecol Cancer"},{"issue":"33","key":"6489_CR8","doi-asserted-by":"publisher","first-page":"3124","DOI":"10.1200\/JCO.19.00674","volume":"37","author":"SCS da Costa","year":"2019","unstructured":"da Costa SCS, Bonadio RC, Gabrielli FCG, Aranha AS, Dias Genta MLN, Miranda VC, et al. Neoadjuvant chemotherapy with cisplatin and gemcitabine followed by chemoradiation versus chemoradiation for locally advanced cervical cancer: a randomized phase II trial. J Clin Oncol. 2019;37(33):3124\u201331.","journal-title":"J Clin Oncol."},{"issue":"16","key":"6489_CR9","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1200\/JCO.2017.75.9985","volume":"36","author":"S Gupta","year":"2018","unstructured":"Gupta S, Maheshwari A, Parab P, Mahantshetty U, Hawaldar R, Sastri Chopra S, et al. Neoadjuvant chemotherapy followed by radical surgery versus concomitant chemotherapy and radiotherapy in patients with stage IB2, IIA, or IIB squamous cervical cancer: a randomized controlled trial. J Clin Oncol. 2018;36(16):1548\u201355.","journal-title":"J Clin Oncol."},{"issue":"6Suppl2","key":"6489_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1634\/theoncologist.6-suppl_2-1","volume":"Suppl2","author":"KH Antman","year":"2001","unstructured":"Antman KH. Introduction: the history of arsenic trioxide in cancer therapy [J]. Oncologist. 2001;Suppl2(6Suppl2):1.","journal-title":"Oncologist"},{"issue":"24","key":"6489_CR11","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1080\/15384101.2017.1387699","volume":"16","author":"Y Shi","year":"2017","unstructured":"Shi Y, Cao T, Huang H. Arsenic trioxide inhibits cell growth and motility via up-regulation of let-7a in breast cancer cells. Cell Cycle. 2017;16(24):2396\u2013403.","journal-title":"Cell Cycle"},{"issue":"6","key":"6489_CR12","first-page":"828","volume":"48","author":"SY Gu","year":"2017","unstructured":"Gu SY, Chen HY, Dai HM. miR-155\/BACH1 signaling pathway in human lung adenocarcinoma cell death induced by arsenic trioxide. Sichuan Daxue Xuebao Yi Xue Ban. 2017;48(6):828\u201333.","journal-title":"Sichuan Daxue Xuebao Yi Xue Ban."},{"issue":"57","key":"6489_CR13","first-page":"141","volume":"17","author":"X Jiang","year":"2017","unstructured":"Jiang X, Chen C, Gu S. Regulation of ABCG2 by nuclear factor kappa B affects the sensitivity of human lung adenocarcinoma A549 cells to arsenic trioxide. Environ Toxicol Pharmacol. 2017;17(57):141\u201350.","journal-title":"Environ Toxicol Pharmacol"},{"key":"6489_CR14","first-page":"612","volume":"21","author":"A Abudoureyimu","year":"2017","unstructured":"Abudoureyimu A, Muhemaitibake A. Arsenic trioxide regulates gastric cancer cell apoptosis by mediating cAMP. Eur Rev Med Pharmacol Sci. 2017;21:612\u20137.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"6489_CR15","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1177\/147323001204000404","volume":"40","author":"XP Sun","year":"2012","unstructured":"Sun XP, Zhang X, He C, Qiao H, Jiang X, Jiang H, et al. ABT-737 synergizes with arsenic trioxide to induce apoptosis of gastric carcinoma cells in vitro and in vivo. J Int Med Res. 2012;40:1251\u201364.","journal-title":"J Int Med Res"},{"key":"6489_CR16","first-page":"638","volume":"06","author":"HB Shao","year":"2004","unstructured":"Shao HB, Xu K, Su HY, et al. Clinical study of lipiodol-arsenic trioxide emulsion in the treatment of primary hepatic carcinoma by interventional ways. J Oncology. 2004;06:638\u201340.","journal-title":"J Oncology"},{"issue":"1","key":"6489_CR17","first-page":"pii1101","volume":"5","author":"EB Duqo","year":"2017","unstructured":"Duqo EB, Yedjou CG, Stevens JJ. Therapeutic potential of arsenic trioxide (ATO) in treatment of hepatocellular carcinoma: role of oxidative stress in ATO-induced apoptosis. Ann Clin Pathol. 2017;5(1):1101.","journal-title":"Ann Clin Pathol"},{"issue":"13","key":"6489_CR18","doi-asserted-by":"publisher","first-page":"2174","DOI":"10.1016\/j.yexcr.2010.04.027","volume":"316","author":"J Indira","year":"2010","unstructured":"Indira J, Gayathri C, Sandeep S. Arsenic trioxide downregulates specificity protein (Sp) transcription factors and inhibits bladder cancer cell and tumor growth. Exp Cell Res. 2010;316(13):2174\u201388.","journal-title":"Exp Cell Res."},{"issue":"1","key":"6489_CR19","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/S0304-3835(02)00039-3","volume":"181","author":"SJ Um","year":"2002","unstructured":"Um SJ, Lee SY, Kim EJ. Down-regulation of human papillomavirus E6\/E7 oncogene by arsenic trioxide in cervical carcinoma cells. Cancer Lett. 2002;181(1):11\u201322.","journal-title":"Cancer Lett"},{"issue":"4","key":"6489_CR20","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.bbrc.2014.08.014","volume":"451","author":"H Wang","year":"2014","unstructured":"Wang H, Gao P, Zheng J. Arsenic trioxide inhibits cell proliferation and human papillomavirus oncogene expression in cervical cancer cells. Biochem Biophys Res Commun. 2014;451(4):556\u201361.","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"6489_CR21","first-page":"637","volume":"20","author":"YH Kang","year":"2008","unstructured":"Kang YH, Lee SJ. Role of p38 MAPK and JNK in enhanced cervical cancer cell killing by the combination of arsenic trioxide and ionizing radiation. Oncol Rep. 2008;20(3):637\u201343.","journal-title":"Oncol Rep"},{"issue":"1","key":"6489_CR22","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.taap.2008.01.041","volume":"230","author":"J Zhou","year":"2008","unstructured":"Zhou J, Ye J, Zhao X, et al. JWA is required for arsenic trioxide induced apoptosis in Hela and MCF-7 cells via reactive oxygen species and mitochondria linked signal pathway [J]. Toxicol Appl Pharmacol. 2008;230(1):33\u201340.","journal-title":"Toxicol Appl Pharmacol"},{"issue":"3","key":"6489_CR23","first-page":"245","volume":"22","author":"B Xu","year":"2006","unstructured":"Xu B, Wang J, Bian DH, et al. Arsenic trioxide induces apoptosis and mechanism of cervical cancer cell line in vitro. J Appl Med. 2006;22(3):245\u20137.","journal-title":"J Appl Med"},{"issue":"1","key":"6489_CR24","first-page":"26","volume":"25","author":"XB Ma","year":"2004","unstructured":"Ma XB, Gu ZY, Song HJ, et al. Effects of arsenic trioxide on hTERT-mRNA expression and telomerase activity in Hela cells. J Mil Med Coll. 2004;25(1):26\u20138.","journal-title":"J Mil Med Coll"},{"issue":"4","key":"6489_CR25","first-page":"369","volume":"38","author":"C Lin","year":"2011","unstructured":"Lin C, La L, Su Z, Shi YH. Effect and mechanism of arsenic trioxide on xenograft of cervical carcinoma in nude mice. Cancer Res. 2011;38(4):369\u201372.","journal-title":"Cancer Res"},{"issue":"20","key":"6489_CR26","first-page":"2480","volume":"20","author":"CY He","year":"2011","unstructured":"He CY, Ni R, Liao L. Effect of arsenic trioxide on immunosuppression of Hela cells in cervical carcinoma. J Mod Integr Tradit West Med. 2011;20(20):2480\u20131.2484.","journal-title":"J Mod Integr Tradit West Med"},{"key":"6489_CR27","doi-asserted-by":"publisher","first-page":"e7586","DOI":"10.1136\/bmj.e7586","volume":"346","author":"A-W Chan","year":"2013","unstructured":"Chan A-W, Tetzlaff JM, G\u00f8tzsche PC, Altman DG, Mann H, Berlin JA, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013;346:e7586.","journal-title":"BMJ."},{"key":"6489_CR28","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.ijrobp.2005.10.019","volume":"65","author":"M Rotman","year":"2006","unstructured":"Rotman M, Sedlis A, Piedmonte MR, et al. A phase III randomized trial of postoperative pelvic irradiation in stage IB cervical carcinoma with poor prognostic features: follow-up of a gynecologic oncology group study. Int J Radiat Oncol Biol Phys. 2006;65:169\u201376.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"6489_CR29","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347.45.","journal-title":"Eur J Cancer."},{"key":"6489_CR30","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. Washington, DC: US Department of Health and Human Services; 2010. https:\/\/www.eortc.be\/services\/doc\/ctc\/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf."},{"key":"6489_CR31","first-page":"697","volume":"09","author":"FL Qu","year":"2011","unstructured":"Qu FL, Hao XZ. A Phase II multicenter clinical study of arsenic trioxide in the treatment of primary liver cancer. Chinese J Oncol. 2011;09:697\u2013701.","journal-title":"Chinese J Oncol"},{"key":"6489_CR32","first-page":"111","volume":"1","author":"HW Cao","year":"2016","unstructured":"Cao HW, Zhao XH, Zhao XH. clinical observation of arsenic trioxide combined with ICE regimen in the treatment of relapsed refractory non-Hodgkin lymphoma. Hainan Med. 2016;1:111\u20133.","journal-title":"Hainan Med"},{"key":"6489_CR33","first-page":"707","volume":"5","author":"XM Yang","year":"2013","unstructured":"Yang XM, Chen YH, Chen YH, et al. Clinical study of arsenic trioxide combined with cisplatin in the treatment of malignant pleural effusion. West China Med J. 2013;5:707\u20139.","journal-title":"West China Med J"},{"key":"6489_CR34","first-page":"502","volume":"10","author":"ZH Zheng","year":"2017","unstructured":"Zheng ZH, Wang XH, Wang XJ. The efficacy of first-line chemotherapy combined with arsenic trioxide in the treatment of metastatic osteosarcoma of the extremities. Chin J Oncol. 2017;10:502\u20137.","journal-title":"Chin J Oncol"},{"key":"6489_CR35","first-page":"901","volume":"6","author":"YJ Liu","year":"2015","unstructured":"Liu YJ, Song WX, Gao F, et al. Efficacy of arsenic trioxide injection combined with chemotherapy in the treatment of advanced gallbladder cancer. Zhejiang Clin Med. 2015;6:901\u20133.","journal-title":"Zhejiang Clin Med"},{"issue":"1","key":"6489_CR36","first-page":"44","volume":"5","author":"XI Zhou","year":"2015","unstructured":"Zhou XI, Chen ZD. Effect and mechanism of different doses of arsenic trioxide alone and combined cisplatin on human cervical cancer transplanted tumor. Chin Med Sci. 2015;5(1):44\u20137.","journal-title":"Chin Med Sci."},{"key":"6489_CR37","first-page":"473","volume":"6","author":"DF Pan","year":"2013","unstructured":"Pan DF, Huang L. Arsenic trioxide enhances radiosensitization of cervical cancer in vitro. J Clin Microbiol. 2013;6:473\u20135.","journal-title":"J Clin Microbiol"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-022-06489-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-022-06489-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-022-06489-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T12:09:43Z","timestamp":1657282183000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-022-06489-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,8]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["6489"],"URL":"https:\/\/doi.org\/10.1186\/s13063-022-06489-1","relation":{},"ISSN":["1745-6215"],"issn-type":[{"type":"electronic","value":"1745-6215"}],"subject":[],"published":{"date-parts":[[2022,7,8]]},"assertion":[{"value":"28 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval has been obtained from the Ethics Committee of the First Affiliated Hospital of Guangzhou University of Chinese Medicine (ZYYECK2019001). All participants signed up for informed consent. All patient personal information and data will be kept confidential after collection.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"556"}}